Table 1

Baseline characteristics by APR levels
Neither APR elevated APR levels discordant Both APR elevated P value
n = 2,520 n = 1,058 n = 650
Age (years) 59.29 ± 13.22 62.21 ± 13.21 62.71 ± 13.34 <0.0001
Duration of RA (years) 11.01 ± 9.83 11.93 ± 10.68 10.91 ± 10.27 0.0406
One-year follow-up duration (days) 362.63 ± 30.51 363.33 ± 31.06 363.46 ± 32.03 0.7410
mHAQ 0.33 ± 0.40 0.45 ± 0.47 0.56 ± 0.54 <0.0001
CDAI 12.89 ± 10.15 15.18 ± 11.16 20.47 ± 14.68 <0.0001
Tender joints 3.73 ± 5.24 4.29 ± 5.40 6.30 ± 7.21 <0.0001*
Swollen joints 4.04 ± 5.13 4.80 ± 5.49 6.64 ± 6.42 <0.0001*
Patient global assessment 30.91 ± 23.82 36.35 ± 25.45 42.90 ± 27.56 <0.0001
MD global assessment 20.21 ± 16.61 24.67 ± 19.06 32.42 ± 22.50 <0.0001
Prednisone use 680 (26.98%) 341 (32.23%) 275 (42.31%) <0.0001
Methotrexate use 1,668 (66.19%) 698 (65.97%) 417 (64.15%) 0.6166
Biologic use 1,263 (50.12%) 447 (42.25%) 224 (34.46%) <0.0001

*Log-linear model (Poisson) - χ2 test. APR, acute phase reactant; RA, rheumatoid arthritis; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.

Kay et al.

Kay et al. Arthritis Research & Therapy 2014 16:R40   doi:10.1186/ar4469

Open Data